title: LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective.
abstract: Evidence supports stereotactic body radiotherapy (SBRT) as a curative treatment option for inoperable early stage non-small-cell lung cancer (NSCLC) resulting in high rates of tumour control and low risk of toxicity. However, promising results are mainly derived from SBRT of peripheral pulmonary lesions, whereas SBRT for the central tumours can lead to severe radiation sequelae owing to the spatial proximity to the serial organs at risk. Robust data on the tolerance of mediastinal structures to high-dose hypofractionated radiation are limited; furthermore, there are many open questions regarding the efficiency, safety and response assessment of SBRT in inoperable, centrally located early stage NSCLC, which are addressed in a prospective multicentre study [sponsored by the European Organization for Research and Treatment of Cancer (EORTC 22113-08113-LungTech)]. In this review, we summarize the current status regarding SBRT for centrally located early stage NSCLC that leads to the rationale of the LungTech trial. Outline and some essential features of the study with focus on a summary of current experiences in dose/fraction-toxicity coherences after SBRT to the mediastinal structures that lead to LungTech normal tissue constraints are provided.
authors: 1 Department of Radiation Oncology, University Medical Center Freiburg, Freiburg, Germany.|2 German Cancer Consortium (DKTK), Heidelberg, Partner Site Freiburg, Germany.
authors: S
authors: S
authors: Adebahr
authors: 3 EORTC Headquarters, Brussels, Belgium.
authors: S
authors: S
authors: Collette
authors: 3 EORTC Headquarters, Brussels, Belgium.
authors: E
authors: E
authors: Shash
authors: 4 Department of Radiation Oncology, Catharina Hospital, Eindhoven, Netherlands.
authors: M
authors: M
authors: Lambrecht
authors: 5 Department of Radiotherapy, Institut Gustave Roussy, Villejuif, France.
authors: C
authors: C
authors: Le Pechoux
authors: 6 Institute of Cancer Sciences, Radiotherapy Related Research, The Christie NHS Foundation Trust and University of Manchester, Manchester, UK.
authors: C
authors: C
authors: Faivre-Finn
authors: 7 KU Leuven-University of Leuven, University Hospitals Leuven, Department of Radiation Oncology, Leuven, Belgium.
authors: D
authors: D
authors: De Ruysscher
authors: 8 Department of Radiation Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
authors: H
authors: H
authors: Peulen
authors: 8 Department of Radiation Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
authors: J
authors: J
authors: Belderbos
authors: 9 Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland.
authors: R
authors: R
authors: Dziadziuszko
authors: 10 Department of Radiology, Allgemeines Krankenhaus Celle, Celle, Germany.
authors: C
authors: C
authors: Fink
authors: 11 Department of Radiation Oncology, University of Zurich, Zurich, Switzerland.
authors: M
authors: M
authors: Guckenberger
authors: 4 Department of Radiation Oncology, Catharina Hospital, Eindhoven, Netherlands.
authors: C
authors: C
authors: Hurkmans
authors: 1 Department of Radiation Oncology, University Medical Center Freiburg, Freiburg, Germany.|2 German Cancer Consortium (DKTK), Heidelberg, Partner Site Freiburg, Germany.
authors: U
authors: U
authors: Nestle
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000601:surgery*; D019583:Dose Fractionation, Radiation; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000601:surgery*; D009367:Neoplasm Staging; D011446:Prospective Studies; D011785:Quality Assurance, Health Care; D016634:Radiosurgery / Q000009:adverse effects / Q000592:standards